EG18388A - Process for preparing cimetidine polymorphic b - Google Patents

Process for preparing cimetidine polymorphic b

Info

Publication number
EG18388A
EG18388A EG439/87A EG43987A EG18388A EG 18388 A EG18388 A EG 18388A EG 439/87 A EG439/87 A EG 439/87A EG 43987 A EG43987 A EG 43987A EG 18388 A EG18388 A EG 18388A
Authority
EG
Egypt
Prior art keywords
polymorphic
cimetidine
preparing
preparing cimetidine
cimetidine polymorphic
Prior art date
Application number
EG439/87A
Other languages
English (en)
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Application granted granted Critical
Publication of EG18388A publication Critical patent/EG18388A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EG439/87A 1986-08-01 1987-07-30 Process for preparing cimetidine polymorphic b EG18388A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868618847A GB8618847D0 (en) 1986-08-01 1986-08-01 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
EG18388A true EG18388A (en) 1992-10-30

Family

ID=10602097

Family Applications (1)

Application Number Title Priority Date Filing Date
EG439/87A EG18388A (en) 1986-08-01 1987-07-30 Process for preparing cimetidine polymorphic b

Country Status (22)

Country Link
US (1) US4996222A (fr)
EP (1) EP0257823B1 (fr)
JP (1) JPH0643304B2 (fr)
KR (1) KR960012397B1 (fr)
CN (1) CN1024497C (fr)
AU (1) AU601206B2 (fr)
CA (1) CA1287802C (fr)
DE (1) DE3778795D1 (fr)
DK (1) DK149988D0 (fr)
EG (1) EG18388A (fr)
ES (1) ES2037086T3 (fr)
GB (1) GB8618847D0 (fr)
GR (1) GR3005298T3 (fr)
HU (1) HU205853B (fr)
IE (1) IE60759B1 (fr)
IL (1) IL83349A (fr)
MY (1) MY100998A (fr)
PH (1) PH23505A (fr)
PT (1) PT85468B (fr)
WO (1) WO1988000825A1 (fr)
ZA (1) ZA875631B (fr)
ZW (1) ZW13587A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
AU627775B2 (en) * 1988-09-20 1992-09-03 Glaxo Group Limited Pharmaceutical compositions
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
CA2121435C (fr) * 1993-04-16 2002-01-22 Sheila M. Ratnaraj Suspension pharmaceutique aqueuse et methode de preparation
AU3154895A (en) * 1994-08-01 1996-03-04 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
GB9504599D0 (en) * 1995-03-03 1995-04-26 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
GB2298365B (en) * 1995-03-03 1997-05-07 Reckitt & Colmann Prod Ltd A liquid pharmaceutical composition alginate and potassium bicarbonate
GB9708772D0 (en) * 1997-04-30 1997-06-25 Reckitt & Colmann Prod Ltd Organic compositions
CN1286468C (zh) * 1997-04-30 2006-11-29 雷克特本克斯尔保健(英国)有限公司 含藻酸或藻酸盐的药物组合物
IN186245B (fr) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US6515008B1 (en) * 2000-05-04 2003-02-04 Smithkline Beecham Corporation Formulation
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
US6930119B2 (en) * 2002-07-17 2005-08-16 Reliant Pharmaceuticals, Inc. Liquid pharmaceutical composition
EP1603579A4 (fr) * 2003-03-10 2006-06-14 Univ Michigan Compositions et methodes d'utilisation de produits d'obturation durale a base d'alginate
US20080095901A1 (en) * 2004-11-02 2008-04-24 Purac Biochem B.V> Method for Stabilizing and Preventing Coagulation of Proteins in Milk
US20060094760A1 (en) * 2004-11-04 2006-05-04 Fawzy Abdel A Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution
EP1745775B1 (fr) * 2005-07-19 2008-05-28 Ethypharm Formulations de rétention gastrique et procédé de préparation
FR2911506B1 (fr) * 2007-01-18 2009-07-03 Ceva Sante Animale Sa Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
US8999395B2 (en) * 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
WO2011031176A1 (fr) * 2009-09-10 2011-03-17 Bial - Portela & C.A., S.A. Formulations de suspension orales d’acétate d’eslicarbazépine
CN111481508A (zh) * 2016-10-19 2020-08-04 萨恩帕斯药物有限公司 针对引起离子通道病的药物的保护性组合物和方法
GB201918617D0 (en) * 2019-12-17 2020-01-29 Reckitt Benckiser Health Ltd Personal lubricant composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56104868A (en) * 1980-01-24 1981-08-20 Fujimoto Seiyaku Kk Conversion between polymorphous crystals of cimetidine
HU185457B (en) * 1981-09-25 1985-02-28 Richter Gedeon Vegyeszet Process for preparating cimetidine-z
CA1239349A (fr) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Compose pharmaceutique contenant de la cimetidine

Also Published As

Publication number Publication date
AU7756487A (en) 1988-02-24
CN1024497C (zh) 1994-05-18
DE3778795D1 (de) 1992-06-11
ES2037086T3 (es) 1993-06-16
DK149988A (da) 1988-03-18
PH23505A (en) 1989-08-16
HU205853B (en) 1992-07-28
JPH0643304B2 (ja) 1994-06-08
WO1988000825A1 (fr) 1988-02-11
US4996222A (en) 1991-02-26
PT85468A (en) 1987-08-01
PT85468B (pt) 1990-06-29
AU601206B2 (en) 1990-09-06
GR3005298T3 (fr) 1993-05-24
IE872077L (en) 1988-02-01
KR880701551A (ko) 1988-11-03
GB8618847D0 (en) 1986-09-10
DK149988D0 (da) 1988-03-18
EP0257823A1 (fr) 1988-03-02
ZA875631B (en) 1989-03-29
JPH01500434A (ja) 1989-02-16
EP0257823B1 (fr) 1992-05-06
IL83349A (en) 1992-03-29
CN87105387A (zh) 1988-02-17
ZW13587A1 (en) 1989-02-15
MY100998A (en) 1991-06-29
CA1287802C (fr) 1991-08-20
IE60759B1 (en) 1994-08-10
HUT46541A (en) 1988-11-28
KR960012397B1 (ko) 1996-09-20

Similar Documents

Publication Publication Date Title
EG18388A (en) Process for preparing cimetidine polymorphic b
EG18230A (en) Process for preparing 3-aryloxy-3-substituted propanamines
YU34587A (en) Process for preparing purinic nucleozides
PT85174A (en) Process for preparing azabiciclic compounds
PT86120A (en) Process for preparing n9-cyclopentyl-adenine derivatives
PT84237A (en) Process for preparing neurite-promoting factor
YU131088A (en) Process for obtaining 1-terciaric-alkyl-substituted naphtiridine- and hynolin-carboxylic intermediers
PT85719A (en) Process for preparing 2-amino-ethylamine derivatives
ZA876516B (en) Process for preparing 3-pyrrolidinols
EP0245960A3 (en) Process for preparing n-acyltetrahydroisoquinoline
EP0267794A3 (en) Process for preparing polyolefins
YU119887A (en) Process for preparing dihydroizoquinolines
EP0237293A3 (en) Process for preparing polyolefins
PT85277A (en) Process for preparing substituted hexahydro arylquinolizines
PT84553A (en) Process for preparing indenopyrimidine derivatives
HUT44238A (en) Process for preparing 1-aryl-5-amino-pyrazole derivatives
YU118187A (en) Process for obtaining mercaptoacylproline
GR870442B (en) Process for preparing methyl isocyanate
PT86424A (en) Process for preparing substituted tetrahydropyridoindoles
YU213887A (en) Process for preparing new 1-aryloxi-3-amino-2-propanoles
GB8730269D0 (en) Process for preparing 16-dehydro-20-oxipregnane derivatives
PT84279A (en) Process for preparing 2-aminoacyloxymethyl-2-penem compounds
PT84383A (en) Process for preparing substituted pyrimidoindoles
YU9187A (en) Process for preparing cimetidine
GR870645B (en) Process for preparing novel ergolene derivatives